Georgia Bio 2019 Legislative Session Recap

The 2019 Georgia 40-day legislative session concluded with Sine Die on Tuesday, April 2nd. This legislative session was characterized by new leadership in the Governor and Lt. Governor’s office, as well as 40 freshman legislators.

Of the eight measures detailed below, there were two for which Georgia Bio actively advocated on behalf of our members and the people of georgia. Our rural teacher training program received state funding to expand an existing pilot training program for high school teachers that specifically addresses the skill and equipment gap. Workforce development and availability is always a top question we must address with life sciences companies seeking new locations, headquarters or expansions. More on this exciting development and program is coming soon.

We also took a supportive stance on HB 63, which helps protect patients from onerous step therapy requirements. That bill was signed into law by Governor Kemp as well.

We thank our legislative affairs team for their tireless work arranging and executing on awareness and importance meetings with appropriation committee members, the Governor’s and Lt. Governor’s offices. We also thank our members who contributed in person to those meetings to ensure the industry’s position and subject matter expertise were well represented in those conversations with our state legislators.

As Georgia Bio closes out a successful legislative session, we will be meeting with and working with as many members as possible during the remainder of the year to discuss top of mind priorities and construct our legislative efforts going into the 2020 session.

Here is a recap of the top life science industry items that made it through the session and were signed into law last month by Governor Kemp.

2019 Legislative Priorities

Rural Teacher Training Program

As many of you are aware, the life sciences industries require many skills that are in the traditional STEM education area, however what is often lacking is practical laboratory technique combined with hands-on laboratory experience. Thanks to the leadership of state appropriators and Governor Brian Kemp, Georgia Bio was able to secure funding in the FY2020 budget to match private funds that will enable Georgia Bio, through the Georgia BioEd Institute in partnership with the Marcus Center for Therapeutic Cell Characterization and Manufacturing at Georgia Tech, to expand an existing pilot training program for high school teachers that specifically addresses the skill and equipment gap. Partnering with the Department of Education and the Georgia Youth Science Centers, year one of the program will provide 8 training workshops in rural school districts impacting roughly 64 high school teachers and reaching over 5,000 students.

BILL MOVEMENT

This session the Georgia Generally Assembly passed legislation that would establish step therapy protocols for patients, provisions for the licensure of genetic counselors, the authorization to submit a Section 1115 waiver request to the United States Department of Health and Human Services Centers for Medicare and Medicaid Services, and modernizing telemedicine policy in Georgia. Please see below for more details on bills that passed out of the 2019 Georgia Legislative Session and signed into law by Governor Kemp.

HB 63 – Health Benefit Plans to Establish Step Therapy Protocols

Georgia Bio Legislative Affairs Committee voted to SUPPORT HB 63, introduced by Representative Sharon Cooper (R – Marietta) establishes step therapy protocols to protect patients from onerous step therapy requirements. Ensures that step therapy protocols are based on clinical guidelines developed by independent experts. Establishes a basic framework for when it is medically appropriate to exempt patients from step therapy, as well as an exceptions process that is transparent and accessible to patients and health care providers. The step therapy bill passed out of the Senate with a vote of 49-0 and House of Representatives with a vote of 165-0 on April 2 nd .

HB 166 – Genetic Counselors Act

Representative Deborah Silcox (R – Sandy Springs) authored HB 166, requiring licensing for genetic counselors, including physicians, assistants and mandates some continuing education requirements. There are approximately 89 genetic counselors in Georgia and all those individuals have master’s degrees for a specialty in genetic counseling and half work in hospitals. The other half of the genetic counselors work out in the field with physicians, primarily, and primary care doctors. They work primarily in three different areas: prenatal care, cardiac care and oncology. HB 166 passed by the House of Representatives by a vote of 148-15 on February 15 th and was adopted by the Senate with a vote of 45-4 on March 11 th .


HB 321 – Extend Sunset for the Hospital Medicaid Financing Program

Authored by Representative Jodi lott (R – Evans) HB 321 extends Georgia’s hospital provide fee through June 30, 2025 to help finance the state’s Medicaid program. In FY 2020, the state expects to collect more than $310 million from the provider fee which it will utilize to draw more than $650 million in federal funds. The bill also includes new financial disclosure and transparency requirements for nonprofit hospitals and the five-year extension of the state’s $60 million rural hospital tax credit. The House of Representatives passed the bill by a vote of 147-19 on February 28 th and was adopted by the senate with a vote of 50-2 on March 29 th .

HB 514 – Georgia Mental Health Reform and Innovation Commission

HB 514 authored by Representative Kevin Tanner (R – Dawsonville) creates the Georgia Mental Health Reform and Innovation Commission. The FY 2020 budget also included several increases for mental health services. The House of Representatives passed the bill by a vote of 152-10 on March 7 th and the Senate adopted with a vote of 52-0 on April 2 nd .

SB 106 – Patients First Act

SB 106 coined the Patients First Act Authored by Senate Blake Tillery (R – Vidalia) authorizes the Department of Community Health to submit a Section 1115 waiver request to the United States Department of Health and Human Services Centers for Medicare and Medicaid Services. This act is a step toward lowering insurance premiums, enhancing access to quality care, and improving health outcomes in every part of our state. The Senate passed the bill by a vote of 35-20 on February 26 th and the House of Representatives adopted with a vote of 104-67 on March 25 th .


SB 115 – “Medical Practice Act of the State of Georgia

SB 115 sponsored by Senator Renee Unterman (R – Buford) aims to provide telemedicine licenses for physicians in other states and for Georgia to engage in the practice of medicine with patients in the state through telemedicine. The Senate passed the bill by a vote of 54-0 on February 26 th and the House of Representatives adopted with a vote of 161-2 on March 29 th .

SB 118 – Georgia Telemedicine Act

Authored by Senator Renee Unterman (R – Buford), SB 118 modernize the Georgia Telemedicine Act by renaming it to the Telehealth Act. The bill provides the definitions of telemedicine and telehealth and would require that all health insurance policies over appropriately provided telehealth services. The Senate passed the bill by a vote of 50-0 on February 26 th and the House of Representatives adopted with a vote of 168-1 on March 25 th .

Micron Biomedical Celebrates the Grand Opening of Its Commercial-Scale Manufacturing Site in Georgia

May 22, 2026
ALPHARETTA, Ga., May 21, 2026 (GLOBE NEWSWIRE) -- Micron Biomedical today announced the grand opening of its world-class manufacturing facility spanning more than 26,000 square feet in Alpharetta, Georgia. The opening marks the most advanced commercial-scale manufacturing site for Micron’s dissolvable vaccine and therapeutic technology in the world and positions the company for pivotal clinical trials that will accelerate the availability of needle-free vaccines and therapeutics that can be self-administered at home. “A significant body of evidence has shown that our dissolvable microarray technology is as effective as — or more effective than — conventionally injected medicines. Parents, patients, government officials, drug developers, public health leaders, and payers also prefer needle-free vaccines and therapeutics that are simpler and more cost-effective to transport and store,” said Steven Damon, CEO of Micron Biomedical . “Our novel technology requires equally innovative manufacturing equipment capable of scaling production, and this facility brings us one step closer to making that vision a reality.” Micron’s technology uses a dissolvable microarray “button” that is applied directly to the skin and, when pressed, painlessly delivers medications that dissolve in the uppermost layers of skin. The facility houses all of the equipment and manufacturing capabilities to design and produce Micron’s technology at scale including R&D facilities, wet labs, dry labs, storage and professional office spaces. Micron Biomedical’s grand opening ceremony was attended by business leaders, elected officials, investors, members of academia and other stakeholders. Representatives from the CDC were also in attendance as recently the CDC launched its first-ever clinical trial of a needle-free vaccine, evaluating a novel rotavirus vaccine, CC24, delivered via Micron Biomedical’s dissolvable microarray technology. The trial, at Emory University, builds on research, published in The Lancet, about self-administered seasonal influenza vaccine via Micron Biomedical’s dissolvable microarray technology, as well as studies across other disease indications, including measles and rubella . “Georgia is emerging as one of the country’s most important biotech manufacturing hubs, attracting talented scientists, engineers, business leaders and creating exciting economic and professional opportunities for our residents,” said Todd Jones, Georgia House Representative . “With its award winning first-in-the industry technology, Micron Biomedical is among the state’s leaders in simultaneously transforming the health of people around the world with never-before-possible access to medicine and vaccines - and in investing in the workforce of tomorrow with high paying jobs and growth opportunities." This year, published research reinforced consumer preference for microarray technology and Micron Biomedical was recognized as the number two most innovative company in its class by Fast Company for addressing global demand for simplified administration and distribution of vaccines and drugs. The scientific community support includes recent commentary in The Lancet which called Micron’s technology “game-changing in humanitarian settings.” Micron’s technology class has also been identified as the highest global priority innovation for overcoming immunization barriers in low- and middle-income countries by the Vaccine Innovation Prioritisation Strategy (VIPS) Alliance. “This milestone reflects the type of coordinated ecosystem growth outlined in Georgia Life Sciences’ recently released Roadmap for Georgia’s Life Sciences Sector — bringing together industry, startups, manufacturers, educators, investors, and policymakers to strengthen the state’s innovation and manufacturing capabilities,” said Maria Thacker Goethe, President and CEO of Georgia Life Sciences , who attended the ribbon cutting ceremony. “With this cutting-edge facility, Micron is helping advance Georgia’s position as a national leader in biotechnology, medical technology, and life sciences innovation while reinforcing the state’s role as a scale-up manufacturing hub for the Southeast.” “Ribbon cuttings are always special and momentous events, but this one is especially satisfying because it points to an infrastructure for pivotal clinical trials of technologies being studied at Emory that have the potential to save lives and reduce disease burden by expanding coverage and access to critical medications,” said Christina Rostad MD, pediatric infectious disease associate professor at Emory University and lead investigator of the CD244 trial who provided commentary remotely. “Our team at Emory University is excited to be a part of the celebration and look forward to continuing to explore the potential of Micron Biomedical’s dissolvable microarray vaccine technology.“ About Micron Biomedical Micron Biomedical is the leader in dissolvable microarray-based, drug and vaccine administration technology with a growing pipeline of needle-free versions of previously injectable-only medicines. Micron Biomedical is a clinical-stage life science company on a rapid path to commercializing its proprietary dissolvable, microarray technology. Micron’s technology is designed to improve access and achieve better health outcomes globally through injection-free, painless, and simple and/or self-administration of drugs and vaccines, and by eliminating or reducing the need for cold chain transport and storage, enhancing safety and efficacy, and improving patient compliance. Micron partners with and/or receives funding from private and public entities including pharmaceutical and biotech companies, the Gates Foundation, the Centers for Disease Control and Prevention (CDC), PATH and the Georgia Research Alliance. For more information visit www.micronbiomedical.com . Press Contact Shira Derasmo M: +1-917-280-2497 E: pr@micronbiomedical.com A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/31153de2-caed-4aa2-b291-ebeed2652b70 A video accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/d855a883-fb26-47ce-9831-8ef1e0b93f43 

Georgia Life Sciences Statement on FDA Commissioner Makary’s Resignation

May 13, 2026
Georgia Life Sciences thanks Dr. Marty Makary for his service as Commissioner of the U.S. Food and Drug Administration during a period of significant change across the nation’s health and regulatory agencies.

Tim Opler to Deliver Keynote at the Georgia Life Sciences Summit

May 12, 2026
Georgia Life Sciences is pleased to announce Tim Opler as a featured keynote speaker at the 2026 Georgia Life Sciences Summit, taking place August 25-26 at the Sandy Springs Performing Arts Center in Atlanta. A leading voice in biotech investment banking, Tim Opler serves as Managing Director in Stifel’s Global Healthcare Group, where he advises innovative life sciences companies on financing, growth strategy, and market positioning across the healthcare landscape. Tim brings deep insight into the evolving biotech investment environment, emerging industry trends, and the factors shaping the future of life sciences innovation and commercialization. Join us for this timely discussion with one of the industry’s most respected financial leaders as we explore the opportunities and challenges defining the next era of life sciences growth . 
MORE POSTS